BioXcel Therapeutics Inc

NASDAQ:BTAI   3:59:58 PM EDT
11.45
0.00 (0.00%)
Products, Regulatory

Bioxcel Therapeutics Announces First Patient Dosed In Tranquility II Phase 3 Trial

Published: 05/03/2022 12:33 GMT
BioXcel Therapeutics Inc (BTAI) - Bioxcel Therapeutics Announces First Patient Dosed in Tranquility Ii Phase 3 Trial for Acute Treatment of Agitation in Patients With Alzheimer’s Disease.
Bioxcel Therapeutics Inc - Top-line Data for Tranquility Ii Anticipated in Q4 2022/early Q1 2023.
Bioxcel Therapeutics Inc - Phase 3 Tranquility Iii Study Underway With Patient Enrollment Initiating in H2 2022.